Gheuens Sarah has recently filed a Form 144 with the SEC, indicating a proposed sale of securities. This filing is significant as it may reflect a strategic shift for the company, particularly within the pharmaceutical sector.
Background
Gheuens Sarah is an entity categorized under the pharmaceutical industry. The company is associated with Agios Pharmaceuticals, Inc., which is identified by CIK 0001439222. The recent filings indicate that Gheuens Sarah is actively engaged in transactions that may affect its operational strategies.
What the Filing Says
The SEC filing dated October 22, 2026, does not provide extensive details about the specific securities being sold. However, it is categorized as a Form 144, which typically reports the proposed sale of securities by an affiliate of a company.
Impact
This proposed sale may impact various stakeholders, including investors and competitors within the pharmaceutical industry. As Gheuens Sarah navigates this process, it could influence market perceptions and competitive dynamics.
What's Next
The filing does not say what happens next.
Filing Details
The Form 144 was filed on October 22, 2026, and accepted by the SEC on the same day at 16:48:54. The filing includes one document, which is categorized as a Form 144 report of proposed sale of securities.
Company Information
Gheuens Sarah is associated with Agios Pharmaceuticals, Inc., which is incorporated in Delaware and has a fiscal year ending on December 31. The company's Central Index Key (CIK) number is 0001881190, and it operates under the Standard Industrial Code (SIC) 2834, which pertains to Pharmaceutical Preparations.
Contact Information
The mailing and business addresses for Gheuens Sarah are both listed as 88 Sidney Street, Cambridge, MA 02139. The business can be contacted at the phone number 617-649-8600.
Absence of Specifics
The filing does not specify the number of shares or the exact nature of the securities being proposed for sale, nor does it provide any details regarding the intended use of the proceeds from the sale.